Status:
UNKNOWN
Serum NGAL IN Patients With Multiple Myeloma
Lead Sponsor:
Assiut University
Conditions:
Multiple Myeloma(MM)
Eligibility:
All Genders
18-75 years
Brief Summary
The aim of this study was to evaluate SERUM neutrophil gelatinase-associated lipocalin, emerging indicator of tubular damage and examine their relationship with established measures of renal function ...
Detailed Description
Multiple myeloma (MM), Being one of the most common hematologic malignancies, particularly in the elderly patient, MM represents a devastating disease that occurs due to uncontrolled proliferation of ...
Eligibility Criteria
Inclusion
- Adult patients (\>18 years) with SMM or overt multiple myeloma (MM will be confirmed based on the WHO diagnostic criteria; the presence of at least 10% plasma cells in bone marrow biopsies, presence of momoclonal protein in serum and /or urine and one of the following disorders (CRAB): hypercalcemia, renal failure, anemia, or lytic bone lesions).
Exclusion
- ( other causes affect NAGAL level )
- Patients with other plasma cell disorders (eg. Waldenstrom macroglobulinuria, MGUS, amyloidosis )
- Recent active infection;
- History of hepatitis B, C, or HIV
- Neoplasms other than myeloma
Key Trial Info
Start Date :
October 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2025
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT05439538
Start Date
October 1 2022
End Date
January 1 2025
Last Update
June 30 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.